Are all aromatase inhibitors alike?

Breast Cancer Research and Treatment

Volumn 112, Issue SUPPL. 1, 2008, Pages 35-43

  Blackwell, Kimberly L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Endocrine therapy; Estrogen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

ARTHRALGIA; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EARLY CANCER; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; METASTASIS; MYALGIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 58249097455     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0233-9     Document Type: Article

References (55)

1. AS Coates A Keshaviah B Thurlimann 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492 10.1200/JCO.2006.08.8617
2. RC Coombes LS Kilburn CF Snowdon 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial Lancet 369 559 570 10.1016/S0140-6736(07) 60200-1
3. A Howell J Cuzick M Baum 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 10.1016/S0140-6736(05)74803-0
4. WR Miller 1999 Biology of aromatase inhibitors: pharmacology/ endocrinology within the breast Endocr Relat Cancer 6 187 195 10.1677/erc.0.0060187
5. J Geisler B Haynes G Anker 2002 Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 751 757 10.1200/JCO.20.3.751
6. Geisler J, Ekse D, Helle H, Eystein-Lonning P (2006) Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res Treat 100(suppl 1) (Abstract 103)
7. Dixon JM, Renshaw L, Young O et al (2006) Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res Treat 100(suppl 1) (Abstract 105)
8. W Eiermann S Paepke J Appfelstaedt 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 1527 1532 10.1023/A:1013128213451
9. MJ Ellis A Coop B Singh 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816
10. IE Smith M Dowsett SR Ebbs 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116 10.1200/JCO.2005.04.005
11. L Cataliotti AU Buzdar S Noguchi 2006 Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative "Arimidex" compared to tamoxifen (PROACT) trial Cancer 106 2095 2103 10.1002/cncr.21872
12. V Semiglazov A Kletsel V Semiglazov 2005 Exemestane vs tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N01, T4N0M0) J Clin Oncol 23 suppl 16 11s (Abstract 530)
13. H Mouridsen M Gershanovich Y Sun 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2596 2606
14. J Bonneterre A Buzdar JM Nabholtz 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2247 2258 10.1002/1097-0142(20011101)92:9<2247::AID- CNCR1570>3.0.CO;2-Y
15. J Bonneterre B Thürlimann JFR Robertson 2000 Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study J Clin Oncol 18 3748 3757
16. JM Nabholtz A Buzdar M Pollak 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial J Clin Oncol 18 3758 3767
17. R Paridaens P Therasse L Dirix 2004 First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)-a randomized phase III trial of the EORTC breast Group J Clin Oncol 22 14S (Abstract 515)
18. C Rose O Vtoraya A Pluzanska 2003 An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole Eur J Cancer 39 2318 2327 10.1016/S0959-8049(03)00630-0
19. B Thürlimann A Keshaviah AS Coates 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258
20. M Baum AU Budzar J Cuzick 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 10.1016/S0140-6736(02)09088-8
21. M Baum A Buzdar J Cuzick 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802 1810 10.1002/cncr.11745
22. ATAC Trialists Group JF Forbes J Cuzick 2007 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07)70385-6
23. Ries LAG, Melbert D, Krapcho M et al (2006) SEER cancer statistics review, 1975-2004. National Cancer Institute, Bethesda, MD. Available via: http://seer.cancer.gov/csr/1975-2004
24. J Mansell IJ Monypenny AI Skene 2006 Predictors of early recurrence in postmenopausal women with operable breast cancer Breast Cancer Res Treat 3 100 (Abstract 2091)
25. L Lamerato S Havstad S Gandhi 2005 Breast cancer recurrence and related mortality in US patients with early breast cancer J Clin Oncol 23 62s (Abstract 738)
26. C Schairer PJ Mink L Carroll SS Devesa 2004 Probabilities of death from breast cancer and other causes among female breast cancer patients J Natl Cancer Inst 96 1311 1321
27. L Mauriac A Keshaviah M Debled 2007 Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Ann Oncol 18 859 867 10.1093/annonc/mdm001
28. Houghton J on behalf of the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trialists' Group (2006) Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T). Ann Oncol 17(suppl 9): ix94 (Abstract 243PD)
29. Melisko M, Lin A, Rugo H (2007) Adjuvant therapy for early stage breast cancer (EBC): distant disease-free survival (DDFS) as a predictor for overall survival (OS). J Clin Oncol 25(18S) (Abstract 583)
30. Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2007) Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjunctive endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. J Clin Oncol 25(18S) (Abstract 538)
31. M Dowsett J Cuzick C Wale 2005 Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study J Clin Oncol 23 7512 7517 10.1200/JCO.2005.01.4829
32. Dowsett M, Allred DC, on behalf of the transATAC investigators (2006) Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100(suppl 1) (Abstract 48)
33. M Dowsett J Houghton C Iden 2006 Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status Ann Oncol 17 818 826 10.1093/annonc/ mdl016
34. R Jakesz W Jonat M Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462 10.1016/S0140-6736(05)67059-6
35. F Boccardo A Rubagotti P Guglielmini 2006 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial Ann Oncol 17 suppl 7 vii10 vii14 10.1093/annonc/mdl941
36. F Boccardo A Rubagotti D Aldrighetti 2007 Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials Cancer 109 1060 1067 10.1002/cncr.22513
37. RC Coombes E Hall LJ Gibson 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 10.1056/NEJMoa040331
38. W Jonat M Gnant F Boccardo 2006 Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis Lancet Oncol 7 991 996 10.1016/S1470-2045(06)70948-2
39. A Buzdar A Howell J Cuzick 2006 Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633 643 10.1016/S1470-2045(06)70767-7
40. PE Goss JN Ingle S Martino 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262 1271
41. Duffy S, on behalf of the ATAC trialists' group (2006) Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years' follow-up. Breast Cancer Res Treat 100(suppl 1) (Abstract 4055)
42. Kieback DG, Harbeck N, Bauer W et al (2007) Endometrial effects of exemestane compared to tamoxifen within the TEAM trial: results of a prospective, randomized study. J Clin Oncol 25(18S) (Abstract 572)
43. Crew KD, Apollo A, Greenlee H et al (2006) Prevalence of joint symptoms in postmenopausal women on aromatase inhibitors for early stage breast cancer. Breast Cancer Res Treat 100(suppl 1) (Abstract 5068)
44. Morales L, Pans S, Westhovens R et al (2006) Importance of synovial fluid retention and thickening in patients with severe musculoskeletal pains treated with letrozole or exemestane: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging. Breast Cancer Res Treat 100(suppl 1) (Abstract 4056)
45. EA Perez RG Josse KI Pritchard 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 3629 3635 10.1200/JCO.2005.05.4882
46. PE Goss S Qi AM Cheung 2004 Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal AI letrozole on bone and lipid metabolism in ovariectomized rats Clin Cancer Res 10 17 5717 5723 10.1158/1078-0432.CCR-04- 0438
47. McCloskey E, Hannon R, Lakner G et al (2007) The letrozole (L), exemestane (E) and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J Clin Oncol 25(18S) (Abstract 555)
48. A Brufsky WG Harker JT Beck 2007 Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer J Clin Oncol 25 829 836 10.1200/JCO.2005.05.3744
49. Brufsky A, Dong M, Lund K (2006) Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 100(suppl 1) (Abstract 5060)
50. N Bundred I Campbell R Coleman 2006 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study) Eur J Cancer Suppl 4 48 (Abstract 12)
51. KM Wasan PE Goss PH Pritchard 2005 The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol 16 707 715 10.1093/annonc/mdi158
52. H Mouridsen A Keshaviah AS Coates 2007 Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial J Clin Oncol 25 5715 5722 10.1200/JCO.2007.12.1665
53. DM Herrington KP Klein 2001 Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function Womens Health Issues 11 95 102 10.1016/S1049-3867(01)00075-5
54. RS Braithwaite RT Chlebowski J Lau 2003 Meta-analysis of vascular and neoplastic events associated with tamoxifen J Gen Intern Med 18 937 947 10.1046/j.1525-1497.2003.20724.x
55. McCloskey E, Hannon R, Lakner G et al (2006) Complete data from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamic (PD) LEAP trial: direct comparison of safety parameters between aromatase inhibitors (AIs) in healthy postmenopausal women. Breast Cancer Res Treat 100(suppl 1) (Abstract 2092)